Full Press Release Details
IDEAYA Advances First in Class PARG Development Candidate, IDE161, into IND Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License.
IDYA
IDEAYA Advances First in Class PARG Development Candidate, IDE161, into IND Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License
Key Takeaway: IDEAYA Advances First in Class PARG Development Candidate, IDE161, into IND Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License
Price reaction · baseline $15.54 (2022-01-28 close) · 1 other IDYA headline(s) in the window, move may be shared
day 0 close
+6.6%
day 1 · peak
+10%
day 3
+0.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma